Tree Diagram

Bio Information is Energy

Cognano is a venture that aims at computer-aided drug discovery. Utilizing large VHH data obtained from alpacas, we are developing a new drug discovery platform to optimize drug design and development. We are actively seeking development partners for our newly identified cancer-specific antigens and antibody drugs. Our focus areas include:

  • Triple-negative breast cancer (TNBC)
  • Pancreatic cancer
  • Small cell lung carcinoma

About us

12Years

Research on VHH Antibodies

50Types

Antigens

300MReads

Antibody Genes

30MClones

Labeled Antibody Sequences

Pitch

London Tech Week was held in June 2024. Six selected ventures from Japan exhibited, one of which was COGNANO. The following video is a pitch video made by the representative of COGNANO at London Tech Week. A blog post here.

VHH Antibody

For DNA organisms including humans, the genome should not change throughout our lives, but only the antibody genes change almost infinitely (hypermutation), and the acquired antibodies fight viruses, bacteria, and cancer. In this meaning, antibodies are amazing nature's masterpiece. Evolutionarily, it originated in cartilaginous fish such as the eight-eyed eel, then evolved into a more complex fo...

Learn more

Projects

A Drug Discovery Paradigm to Solve Unmet Medical Needs
The senshu ikeda bank
  • Research Grant
Development of "Smart VHH-ELISA" by upgrading the sandwich method using alpaca VHH antibody
R&D support project for growing small and medium-sized enterprises (Go-Tech Project, Ministry of Economy, Trade and Industry)
  • Research Grant
Certified as A-rank by the Kyoto City Venture Business Connoisseur Committee
Kyoto City
  • Research Grant
  • Certification
Development of methodologies to improve efficiency of alpaca breeding
Laboratory of Reproductive Biology, Graduate School of Agriculture,Kyoto-Univ(Naojiro Minami Professor)
  • Joint Research
Development of a device to test for environmental viruses in sewage
Project grants for industry-academia-government promotion by Kyoto-sangyo 21
  • Research Grant

Synergy between immune response and machine learning

Vertebrates have the ability to make complex (full-bodied) antibodies composed of light and heavy chains, but only camelids have single-domain antibodies in addition to full-bodied antibodies. Single domain antibodies can be easily made into a gene library from lymphocyte genes, and antibodies created by immunized camelids will be big data.

Biopanning-labeled data using intermolecular interactions (antigen-antibody reactions) are integrated by COGNANO's unique algorithm, making it possible to predict the binding characteristics (binding affinity, epitope) to antigen molecules.COGNANO's original platform that can calculate antibody characteristics by machine learning huge amounts of real antibody data and provide them as seeds at high speed.

Even if the naive library, which is not immunized, is analyzed, it cannot be used as teaching data for machine learning because the number of types of binding antibodies is too small. Our Cognano VHH platform make it possible to discover target antibodies 10K times effectively compared with conventional mouse or human antibody platforms.